Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Imbruvica

(im-BROO-vih-kuh)
A drug used alone or with other drugs to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Waldenstrom macroglobulinemia (a type of non-Hodgkin lymphoma). It is also used to treat adults and children aged 1 year and older with chronic graft versus host disease. It is also being studied in the treatment of other types of cancer. Imbruvica blocks a protein called BTK, which may help keep cancer cells from growing. It may also lower the body’s immune response. Imbruvica is a type of tyrosine kinase inhibitor. Also called ibrutinib.
More Information
Search NCI's Dictionary of Cancer Terms